Form 8-K · Current report
Pfizer 8-K, filed Aug 4, 2026
- Filed
- CIK
- 0000078003
- Accession no.
- 0000078003-26-000094
Summary
Pfizer reported second-quarter 2026 revenues of $15.0 billion, up 1% operationally and 3% as reported, with a reported loss per share of $0.04 reflecting $4.3 billion in non-cash intangible asset impairments and adjusted diluted EPS of $0.77. The company raised its full-year 2026 revenue guidance midpoint by $500 million to a range of $60.5 to $62.5 billion, reaffirmed adjusted diluted EPS guidance of $2.80 to $3.00 (absorbing roughly $0.10 from the Innovent Biologics transaction), and announced an additional $2.5 billion in anticipated productivity savings expected from 2027 through 2029.
Key points
- Second-quarter 2026 revenues of launched and acquired products grew 18% operationally; excluding Comirnaty and Paxlovid, total revenues grew 5% operationally.
- Paxlovid revenues fell 95% operationally and Comirnaty fell 34% operationally, and the full-year COVID-19 product revenue expectation was cut to about $4 billion from about $5 billion.
- Guidance reflects roughly $1.5 billion better-than-expected non-COVID product performance and a $650 million acquired in-process R&D charge from the completed Innovent Biologics licensing agreement, to be recorded in the third quarter of 2026.
- Chairman and CEO Albert Bourla said the obesity program is advancing and the oncology portfolio remains a source of strength.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On August 4, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the second quarter of 2026. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein. The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.